Related Experiment Video

Updated: May 16, 2026

Stem Cell-Derived Viral Ag-Specific T Lymphocytes Suppress HBV Replication in Mice
07:25

Stem Cell-Derived Viral Ag-Specific T Lymphocytes Suppress HBV Replication in Mice

Published on: September 25, 2019

Management of hepatitis C in HIV and/or HBV co-infected patients

José Vicente Fernández-Montero1, Vicente Soriano

  • 1Department of Infectious Diseases, Hospital Carlos III, Calle Sinesio Delgado 10, Madrid 28029, Spain.

Best Practice & Research. Clinical Gastroenterology
|December 4, 2012
PubMed

Insights

Co-infection with HIV or HBV in hepatitis C patients amplifies liver damage and cancer risk. New direct-acting antivirals (DAAs) show promise for HIV-HCV co-infections, but further trials are needed to confirm benefits and monitor HBV rebounds.

Area of Science:

  • Hepatology
  • Virology
  • Infectious Diseases

Background:

  • Co-infection with human immunodeficiency virus (HIV) or hepatitis B virus (HBV) is common in chronic hepatitis C patients due to shared transmission routes.
  • Viral interactions in co-infections often exacerbate liver damage, increasing risks of end-stage liver disease and hepatocellular carcinoma.
  • HIV-HCV co-infection is linked to reduced effectiveness of antiviral therapies.

Purpose of the Study:

  • To review the impact of viral co-infections (HIV, HBV) on chronic hepatitis C (HCV) patients.
  • To discuss the implications of direct-acting antivirals (DAAs) in managing HCV co-infections.
  • To highlight the need for further research on DAA efficacy and safety in dually infected populations.

Main Methods:

  • Literature review of studies on viral co-infections in hepatitis C.
  • Analysis of treatment outcomes for co-infected patients.
  • Evaluation of current evidence for direct-acting antiviral (DAA) use.

Main Results:

  • Co-infections with HIV or HBV significantly increase liver damage and cancer risk in HCV patients.
  • HIV-HCV co-infection is associated with poorer responses to standard antiviral treatments.
  • Evidence suggests DAAs may be beneficial for HCV in dually infected patients, but require further investigation.

Conclusions:

  • Management of co-infected patients requires careful consideration of individual viral replication and disease status.
  • New direct-acting antivirals (DAAs) offer potential therapeutic advances for HCV co-infections.
  • Prospective trials are essential to validate DAA efficacy and monitor for potential hepatitis B virus (HBV) rebounds.

More Related Videos

A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target11:34

A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target

Published on: May 10, 2022

"Liver-on-a-Chip" Cultures of Primary Hepatocytes and Kupffer Cells for Hepatitis B Virus Infection10:25

"Liver-on-a-Chip" Cultures of Primary Hepatocytes and Kupffer Cells for Hepatitis B Virus Infection

Published on: February 19, 2019

Related Concept Videos

Hepatitis01:25

Hepatitis

Hepatitis is an inflammatory condition of the liver most commonly caused by hepatotropic viruses (A–E), though non-infectious causes such as alcohol and drugs also exist.Hepatitis AHepatitis A virus (HAV) is a non-enveloped RNA virus of the Picornaviridae family. It is primarily transmitted via the fecal-oral route, typically through ingestion of contaminated food or water. After ingestion, HAV enters the bloodstream through the oropharynx or intestinal epithelium and reaches the liver. The...
Viral Hepatitis I: Introduction01:28

Viral Hepatitis I: Introduction

Viral hepatitis is an inflammatory condition of the liver caused by infection with hepatotropic viruses, most commonly hepatitis A, B, C, D, and E. Despite variations in structure and transmission, all viruses mentioned infect hepatocytes and provoke immune responses that can hinder liver function. Additionally, some non-hepatotropic viruses can also lead to hepatic inflammation.Hepatitis A VirusHepatitis A virus (HAV) is transmitted through the fecal–oral route, typically by ingestion of food...
Retrovirus Life Cycles01:10

Retrovirus Life Cycles

Retroviruses have a single-stranded RNA genome that undergoes a special form of replication. Once the retrovirus has entered the host cell, an enzyme called reverse transcriptase synthesizes double-stranded DNA from the retroviral RNA genome. This DNA copy of the genome is then integrated into the host’s genome inside the nucleus via an enzyme called integrase. Consequently, the retroviral genome is transcribed into RNA whenever the host’s genome is transcribed, allowing the retrovirus to...
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow01:26

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug binding...
Esophageal Varices-II: Clinical Features and Management01:28

Esophageal Varices-II: Clinical Features and Management

Esophageal varices often manifest as gastrointestinal bleeding episodes, presenting symptoms like hematemesis (vomiting of blood), hematochezia (passing fresh blood via the rectum), and melena (black, tarry stools). Other signs can include weight loss, anorexia, abdominal discomfort, jaundice, pruritus, altered mental status, and muscle cramps.
In the initial assessment, a thorough review of the patient's medical history is vital to identify risk factors such as liver disease, alcohol abuse, or...
Pulmonary Tuberculosis V01:28

Pulmonary Tuberculosis V

Medical management of tuberculosis (TB) patients involves a comprehensive approach that includes diagnosis, treatment, and monitoring. The specific strategies can vary depending on the type of tuberculosis (latent or active), the patient's overall health status, and other considerations.
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the progression...